
Nuvation Bio Inc. (NYSE:NUVB – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for Nuvation Bio in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.34) for the year, down from their prior forecast of ($0.33). HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.13) EPS.
Nuvation Bio (NYSE:NUVB – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%.
Read Our Latest Stock Report on Nuvation Bio
Nuvation Bio Stock Performance
Shares of NUVB stock opened at $4.16 on Monday. The company has a quick ratio of 7.30, a current ratio of 7.45 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average price of $5.39 and a two-hundred day moving average price of $5.37. Nuvation Bio has a 12-month low of $3.97 and a 12-month high of $9.75. The firm has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 1.73.
Institutional Investors Weigh In On Nuvation Bio
Institutional investors have recently bought and sold shares of the stock. ACT Capital Partners L.P. bought a new position in Nuvation Bio during the 3rd quarter worth approximately $3,245,000. Alps Advisors Inc. lifted its position in Nuvation Bio by 32.2% in the third quarter. Alps Advisors Inc. now owns 465,179 shares of the company’s stock valued at $2,605,000 after purchasing an additional 113,184 shares during the last quarter. Torray Investment Partners LLC bought a new stake in Nuvation Bio in the third quarter valued at approximately $1,539,000. Profund Advisors LLC lifted its position in Nuvation Bio by 297.6% in the third quarter. Profund Advisors LLC now owns 240,483 shares of the company’s stock valued at $1,347,000 after purchasing an additional 179,994 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in shares of Nuvation Bio by 847.9% during the third quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock valued at $47,000 after purchasing an additional 7,504 shares during the period. 61.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the transaction, the insider directly owned 100,000 shares of the company’s stock, valued at approximately $709,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 30.11% of the company’s stock.
Key Stories Impacting Nuvation Bio
Here are the key news stories impacting Nuvation Bio this week:
- Positive Sentiment: IBTROZI revenue grew 18% sequentially. Management also outlined the possibility of European approval in the first half of 2027, which could trigger an approximately $30 million milestone payment. Article: Nuvation Bio outlines potential Europe approval and IBTROZI growth
- Positive Sentiment: Nuvation Bio reported a third-quarter loss of $0.12 per share, while revenue of $44.95 million exceeded analyst estimates cited in the company’s earnings coverage. The loss was narrower than a year earlier. Article: Nuvation Bio reports Q3 loss and revenue
- Neutral Sentiment: H.C. Wainwright reiterated its Buy rating and $21 price target, although it trimmed its Q1 2027 EPS estimate to break-even from $0.01. Article: Nuvation Bio gets a Buy from H.C. Wainwright
- Neutral Sentiment: RBC lowered its price target from $20 to $17 but maintained an Outperform rating. B. Riley also reduced its target, from $14 to $13, while keeping its Buy rating. The lower targets are a cautionary note, though both firms remain positive on the shares. Article: B. Riley adjusts Nuvation Bio price target
Nuvation Bio Company Profile
Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.
Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.
Further Reading
- Five stocks we like better than Nuvation Bio
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
